Rabies Vaccine Market

Global Rabies Vaccine Market was worth USD 778.60 Million in 2017 and it is expected to reach USD 1292.62 Million by the end of 2027 with the CAGR of 5.2% during the Forecast Period. 

Global Rabies Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027, Rising government initiative for the prevention of rabies disease, adoption of street dogs as pets, and emerging research & development for generating cost-effective treatment and new launch of programs has driven the growth of global rabies vaccine market. 

Scope of Global Rabies Vaccine Market Report-

Rabies is a viral disease that causes inflammation of brain to all human and mammals. Rabies can cause by the rabies virus, lyssaviruses and Australian bat lyssaviruses. Symptoms that are shown in rabies infected person are vomiting, fear of water, loss of consciousness, nausea and violent moments. To cure from virus the rabies vaccine helps to prevent before or long period of time after the exposure to the virus which is caused by the bite of bat or dogs. The vaccines are given along with the rabies immunology for the one who are at the high risk to the exposure. Vaccinating dogs are very effective and can prevent from spreading rabies as they are more prone to this disease. This virus is mainly found in bats, dogs, foxes, and raccoons which have various variants of rabies and can spread in the large population of wildlife too.

 However, the diploid cell rabies vaccine, purified chicken embryo cell vaccine and purified vero cell rabies vaccines are available and are also recommended by world health organization. The first rabies vaccine was launched in 1885 and continued its upgrade version in 1908 and was developed by the French scientist, Emile Roux and Louis Pasteur. The first cell culture vaccine was launched in the year 1980.

 COVID-19 pandemic has shown the negative impact on the global rabies vaccine market; this is due to the shortage of supply for raw material, supply chain disturbance, labor unavailability and broken chain of transportation. Along with this the manufacturing units were shut down which hampered the production due to the strict regulations given by government. 

Global Rabies Vaccine Market Segmentation: -

Global rabies vaccine market is segmented on the basis of product type, vaccination, end user and region and country level. Based on the product type the global rabies vaccine market is classified into chick embryo cell rabies vaccine, vero cell rabies vaccine, baby hamster vaccine and others. Based on the vaccine the global rabies vaccine market is classified into post-exposure prophylaxis, neutral vaccine, non-neutral vaccine, pre-exposure vaccine and others. Based on the end user the global rabies vaccine market is classified into hospitals, clinics, and others. 

By Product Type:

• Chick Embryo Cell Rabies Vaccine
• Vero Cell Rabies Vaccine
• Baby Hamster Vaccine
• Others

By Vaccine:

• Post-Exposure Prophylaxis
• Neutral Vaccine
• Non-Neutral Vaccine
• Pre-Exposure Vaccine
• Others

By End User:

• Hospitals
• Clinics
• Others 

Rabies Vaccine Manufacturers

Some major key players for global rabies vaccine market report cover prominent players like

•  Sanofi S.A,
• GlaxoSmithKline plc,
• Chiron Behring Vaccines Private Limited,
• Elanco,
• Zoetis,
• Cadila Pharmaceuticals Ltd.,
• Serum Institute of India,
• Berna Biotech Ltd.,
• others

News:

Valneva and Bavarian Nordic announced their partnership for distribution & marketing against the rabies vaccine and tick borne vaccine.

June, 18th 2020:  The two global leaders Bavarian Nordic and Valneva have announced their partnership in further marketing and distribution of commercial products. This partnership benefits both companies with the significant commercial synergy, critical mass and leading position in vaccine industry. The partnership will provide vaccination against rabies, cholera, tick-borne encephalitis and Japanese encephalitis in countries of Europe and Canada. Valneva will assume responsibility for distribution & marketing of Bavarian Nordic vaccines for rabies and tick-borne encephalitis. Similarly Bavarian Nordic will transfer the distribution & marketing for Rabipur/RabAvert, & Encepur from GSK. Also Bavarian Nordic has assumed the marketing and distribution of Valneva vaccines for Japanese Encephalitis and cholera in Germany and Switzerland. 

Emerging research & development for generating cost-effective treatment and new launch of programs and rising government initiative for prevention of rabies disease, adoption of street dogs as pets, and has driven the growth of global rabies vaccine market.

New launch of programs and Emerging research & development for generating cost effective treatment has boosted this rabies vaccine market. Rabies remains the global threat killing approximately 59,000 people every year.  WHO, OIE, FAO, and global alliance for rabies control have developed a strategic plan zero by 30 programs. This plan will works for eradication of humans death from rabies infected dogs.  According to the OIE, almost 99% of human rabies is caused by infected dog bites in which 40% of them are children living in the Asia and Africa. The treatment cost per person in rabies endemic countries is USD 108.07 and can raise up to 597.36 USD. The cost of the total plan is 49.7 million dollar which is divided in three phases. 

Other factors that boost the market are rising government initiative for prevention of rabies disease and adoption of street dogs. China has stepped ahead with the prevention from rabies. Country has established a goal of dog vaccination program globally. Chinese scientist has developed a novel rabies vaccine, a live and attenuated vaccine in Wuhan Institute of virology which is known as VEEV-RABV-G. According to the NCBI, almost 59,000 - 61,000 human deaths occurred per year globally by rabies disease. WHO mandates that 80% of the dogs should get vaccinated yearly to break the chain of transmission. 

As animal population increase and dogs are more prone to disease like rabies, adopting dogs can be the best solution. Almost, 25 million dogs are present world-wide. According to WHO, around 1.75 million dog bites occur every year. However, factors that restrain the market from growth are the high cost of the treatment and lack of awareness and knowledge about rabies in emerging countries including the lack of supply. Additionally, increase in investment & surge in R&D activities and collaboration of market players for the advancement in rabies vaccines rea expected to create ample opportunities over the forecast period. 

North America has sustaining dominance on the global rabies vaccine market.

North America is expected to account for the major market share owing to the high awareness of healthcare expenditure among people, presence of key players, and rising investment by government to eradicate rabies is expected to proliferate the market growth in region. In addition, high standard of living along with the increased adoption of pets in the region has created the demand for rabies vaccine market. For instance as per American Society for the Prevention of Cruelty to Animals report 2021 there were around 37%-47% of households in the US have dogs as pet. Other factors that drive this market is the investment done by the government in the healthcare institution and public sectors for eradication of the rabies diseases. For instance, Centers for Disease Control and Prevention, CDC and U.S. department of agriculture Animal and Plant Health Inspection Service have signed first the American Rabies Management Plan with Mexican and Canadian authorities. The main motto of this plan is rabies prevention & control, surveillance & monitoring etc.

 Asia pacific is expected to witness the significant growth in this global rabies vaccine market. This market is rising mostly by the manufacturers in countries like India, China, Japan and development of the vaccines and its substitutes.  According to the economic times, Bharat biotech has launched ChiroRab an anti- rabies vaccine and has become a largest manufacturer in world. This additional investment has increased the production capacity of over 15 million doses annually In India. According to the WHO, India accounts for 36% death due to rabies and had also set a target of eliminating the disease in South- East Asia. Additionally, a development of the next generation vaccine against human rabies based on single dose of a chimpanzee adenovirus vector serotype C (ChAd) is a very simple and effective vaccine strategy to prevent from the virus. ChAd6 is used against rabies. 

The regions covered in this global rabies vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East ,GCC, (UAE, Saudi Arabia, Kuwait) Africa, etc. 

North America

•  U.S.
• Canada

Europe

•  Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific 

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America 

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa 

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA 

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 778.60 Million
Base year considered	2020
Forecast Period CAGR %:	5.2%
Market Size Expected in 2027:	USD 1292.62 Million
Tables, Charts & Figures:	175
Pages	200
Rabies Vaccine Manufacturers	Sanofi S.A, GlaxoSmithKline plc, Chiron Behring Vaccines Private Limited, Elanco, Zoetis, Cadila Pharmaceuticals Ltd., Serum Institute of India, Berna Biotech Ltd., others
Segments Covered	By Product Type, By Vaccine, By End User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

 Key Benefits for Global Rabies Vaccine Market Report–

• Global Rabies Vaccine Market report covers in-depth historical and forecast analysis.
• Global Rabies Vaccine Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Rabies Vaccine Manufacturers, Competitive Analysis, Regional and Country Level.
• Global Rabies Vaccine Market report helps to identify opportunities in the marketplace.
• Global Rabies Vaccine Market report covers an extensive analysis of emerging trends and competitive landscape.